Evidence map›Paper›PMID 33957633›Full record

ArticleOncology2021

BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort.

Maria Vassilakopoulou, Minhee Won, Walter J Curran, Luis Souhami, Michael D Prados, Corey J Langer, David L Rimm, Jason A Hanna, Veronique M Neumeister, Edward Melian and 8 more

Open access · hybridAbstract read
In one paragraph

Article in Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Role of BRCA1 in glioblastoma etiology.Cellular oncology (Dordrecht, Netherlands) · 2024
    Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 16 institutions in 3 countries.

Maria VassilakopoulouDepartment of Pathology, Yale University, New Haven, Connecticut, USA, marva-1@hotmail.com.
Minhee WonNRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.
Walter J CurranDepartment of Radiation Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Luis SouhamiDepartment of Radiation Oncology, McGill University, Montréal, Québec, Canada.
Michael D PradosDepartment of Neurological Surgery, University of California, San Francisco, California, USA.
Corey J LangerDivision of Hematology Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
David L RimmDepartment of Pathology, Yale University, New Haven, Connecticut, USA.
Jason A HannaDepartment of Pathology, Yale University, New Haven, Connecticut, USA.
Veronique M NeumeisterDepartment of Pathology, Yale University, New Haven, Connecticut, USA.
Edward MelianDepartment of Radiation Oncology, Loyola University Medical Center, Maywood, Illinois, USA.
Aidnag Z DiazDepartment of Radiation Oncology, Rush University Medical Center, Chicago, Illinois, USA.
James N AtkinsSoutheast Cancer Consortium-Upstate NCORP, Winston-Salem, North Carolina, USA.
Lydia T KomarnickyDepartment of Radiation Oncology, Drexel University School of Medicine, Philadelphia, Pennsylvania, USA.
Christopher J SchultzDepartment of Radiation Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Steven P HowardDepartment of Human Oncology, University of Wisconsin Hospital, Madison, Wisconsin, USA.
Peixin ZhangNRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania, USA.
Adam P DickerDepartment of Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Jonathan P S KniselyDepartment of Radiation Oncology, Weill Cornell Medicine, New York, New York, USA.
NRG Oncology · USYale University · USCornell University · USDrexel University · USEmory University · USLoyola University Medical Center · USMcGill University · CAMedical College of Wisconsin · USPurdue University West Lafayette · USRush University Medical Center · USSoutheast Clinical Oncology Research Consortium · USThomas Jefferson University · USUniversity of California, San Francisco · USUniversity of Crete · GRUniversity of Pennsylvania · USUniversity of Wisconsin–Madison · US

Funding

NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Statistics CoreU10CA180822 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Mei-Yin C Polley · 2014 to 2026
$146.4M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
NCI NIH HHS U10 CA180822NCI NIH HHS U10 CA180868NCI NIH HHS UG1 CA189867
6 · The paper itself

Abstract

purposeGlioblastoma, the most common malignant brain tumor, was associated with a median survival of <1 year in the pre-temozolomide (TMZ) era. Despite advances in molecular and genetic profiling studies identifying several predictive biomarkers, none has been translated into routine clinical use. Our aim was to investigate the prognostic significance of a panel of diverse cellular molecular markers of tumor formation and growth in an annotated glioblastoma tissue microarray (TMA). METHODS AND MATERIALS: A TMA composed of archived glioblastoma tumors from patients treated with surgery, radiation, and non-TMZ chemother-apy, was provided by RTOG. RAD51, BRCA-1, phosphatase and tensin homolog tumor suppressor gene (PTEN), and miRNA-210 expression levels were assessed using quantitative in situ hybridization and automated quantitative protein analysis. The objectives of this analysis were to determine the association of each biomarker with overall survival (OS), using the Cox proportional hazard model. Event-time distributions were estimated using the Kaplan-Meier method and compared by the log-rank test.

resultsA cohort of 66 patients was included in this study. Among the 4 biomarkers assessed, only BRCA1 expression had a statistically significant correlation with survival. From univariate analysis, patients with low BRCA1 protein expression showed a favorable outcome for OS (p = 0.04; hazard ratio = 0.56) in comparison with high expressors, with a median survival time of 18.9 versus 4.8 months.

conclusionsBRCA1 protein expression was an important survival predictor in our cohort of glioblastoma patients. This result may imply that low BRCA1 in the tumor and the consequent low level of DNA repair cause vulnerability of the cancer cells to treatment.

Indexed as

AdolescentAdultAgedBiomarkers, TumorBrain NeoplasmsBRCA1 ProteinCohort StudiesCombined Modality TherapyFemaleGlioblastomaHumansKaplan-Meier EstimateMaleMiddle AgedProportional Hazards ModelsTissue Array AnalysisBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBiomarkerBRCA1GlioblastomaTissue microarrays

Identifiers

PMID33957633
PMCPMC8491475
OpenAlexW3158774833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.